Who Owns Ginkgo Bioworks Stock?
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 73.73%
- Held by insiders
- 4.43%
- Institutional holders
- 252
- Institutions 73.7%
- Insiders 4.4%
- Public and other 21.8%
Who owns Ginkgo Bioworks stock?
Institutional investors own about 73.7% of Ginkgo Bioworks's shares, spread across 252 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 4.43% of DNA.
The largest institutional holders are Blackrock Inc. (7.73%), Viking Global Investors, L.P. (6.46%) and Erste Asset Management GmbH (4.58%). Together, the top 10 institutions control 39.7% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their DNA positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of DNA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 4.28M | 7.73% | +17.6% |
| Viking Global Investors, L.P. | 3.58M | 6.46% | 0.0% |
| Erste Asset Management GmbH | 2.54M | 4.58% | +30.3% |
| BAILLIE GIFFORD & CO | 2.39M | 4.32% | 0.0% |
| Vanguard Capital Management LLC | 2.09M | 3.77% | +9.0% |
| Anchorage Capital Group, LLC | 1.75M | 3.15% | 0.0% |
| Legal & General Group PLC | 1.67M | 3.01% | +0.5% |
| State Street Corporation | 1.47M | 2.66% | +9.3% |
| Geode Capital Management, LLC | 1.22M | 2.21% | +21.1% |
| Forbes, J.M. & Company | 999.91K | 1.81% | -2.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of DNA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.49M | 2.69% |
| iShares Trust-iShares Russell 2000 ETF | 1.23M | 2.23% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 550.07K | 0.99% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 523.15K | 0.94% |
| PIMCO Equity Series-PIMCO RAE US Small Fund | 506.31K | 0.91% |
| iShares Trust-iShares Russell 2000 Value ETF | 441.78K | 0.80% |
| iShares Trust-iShares Biotechnology ETF | 376.37K | 0.68% |
| EXCHANGE TRADED CONCEPTS TRUST-ROBO Global Artificial Intelligence ETF | 355.18K | 0.64% |
| SPDR SERIES TRT-State Street SPDR S&P Kensho New Economies Composite E | 324.38K | 0.59% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 258.47K | 0.47% |
Frequently asked questions
Who is the largest shareholder of Ginkgo Bioworks?
Blackrock Inc. is the largest institutional shareholder of DNA, owning 7.73% of shares outstanding (4.28M shares) as of its latest 13F filing.
What percentage of Ginkgo Bioworks is owned by institutions?
Institutions own about 73.7% of DNA shares and 77.2% of the public float.
How much of Ginkgo Bioworks do insiders own?
Insiders, such as officers and directors, own about 4.43% of DNA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.